The use of Udiliv is associated with therapeutic areas involving the hepatobiliary system, including the liver, gallbladder, and bile ducts. The medication is commonly used across three main therapeutic areas relevant to the hepatobiliary system. This treatment plays a role in managing conditions such as Primary Biliary Cholangitis (PBC), may assist with the dissolution of specific cholesterol gallstones, and is relevant for supportive care for liver complications associated with cystic fibrosis in children.

“This supportive therapy assists with maintaining functional stability in the liver, which is the primary goal in chronic progressive biliary diseases.”

The core benefit supports general well-being during symptomatic phases and helps improve day-to-day comfort during symptomatic periods. It is often used when supportive symptom management is appropriate, offering relief that helps patients cope more steadily with difficult episodes.

---

Quick Fact: Relief for Systemic Imbalance Udiliv helps address symptom clusters that may become intense or disruptive by assisting with managing symptoms related to systemic imbalance.

Contraindications for Use

Udiliv (Ursodeoxycholic Acid) must not be used in individuals with specific pre-existing conditions, as mandated by regulatory documents. Contraindications include acute inflammation of the gallbladder or bile ducts, biliary tract obstruction, or a non-functioning gallbladder. Use is also prohibited if the patient has calcified (radio-opaque) gallstones or experiences frequent episodes of biliary colic. Absolute contraindication applies to patients with decompensated hepatic cirrhosis in advanced Primary Biliary Cholangitis, as well as those with known hypersensitivity to the active substance or its components.

---

Population and Age Restrictions

Use is generally established for adults for approved indications. However, in the pediatric population, use is restricted to children and adolescents aged 6 years to less than 18 years only for hepatobiliary disorders associated with cystic fibrosis. For all other indications, use in children is generally considered not established. The medicine must not be used during pregnancy; women of childbearing potential must use reliable contraception, which must be non-hormonal when treating gallstones.

The official regulatory profile for Udiliv, which contains Ursodeoxycholic Acid (UDCA), details several interactions primarily related to intestinal absorption and the mechanism of cholesterol dissolution.

---

Interactions Affecting Udiliv's Absorption

Co-administration with bile acid sequestering agents (e.g., Cholestyramine, Colestipol) or aluminum-based antacids (e.g., Aluminum hydroxide) is documented to reduce the intestinal absorption of UDCA. This is a pharmacokinetic interaction that diminishes the amount of the active substance available to exert its intended effect. To manage this interaction, a mandatory timing rule applies: the absorption-reducing agents must be taken at least two hours before or two hours after the dose of Udiliv.

Pharmacodynamic Counteraction

Certain medicinal products are officially noted for counteracting the efficacy of UDCA, particularly when it is used for cholesterol gallstone dissolution. This includes oestrogenic hormones, hormonal oral contraceptives, and some lipid-lowering drugs like Clofibrate. These substances increase the saturation of cholesterol in the bile, which directly opposes UDCA's action of dissolving cholesterol stones.

---

Interactions Affecting Co-administered Drugs

UDCA has been shown to alter the systemic exposure of other co-administered drugs:

Co-administered Drug/Class	Officially Documented Interaction Outcome
Ciclosporin (Immunosuppressant)	Increases the absorption and may lead to higher blood concentrations.
Nitrendipine (Calcium Antagonist)	Reduces the plasma peak concentration (C max) and the area under the curve (AUC).
Ciprofloxacin, Dapsone (Antibiotics)	Reduces absorption or reduces the therapeutic effect (isolated cases reported).
Rosuvastatin (Lipid-lowering)	Slightly elevated plasma levels observed.

Although an initial potential for UDCA to induce Cytochrome P450 3A (CYP3A) enzymes was considered, controlled clinical trials have demonstrated that UDCA does not have a relevant inductive effect on these enzymes.

How Udiliv Works

Udiliv's action, driven by Ursodeoxycholic Acid (UDCA), is based on a multifaceted pharmacodynamic profile that corrects bile composition and exerts cytoprotective action on hepatobiliary cells. The mechanism acts exclusively within the enterohepatic system, modulating critical processes at the molecular and cellular level.

️ Cytoprotection and Anti-Apoptotic Mechanism

The molecule incorporates into cellular and mitochondrial membranes, physically stabilizing them against damage from toxic bile acids. This prevents the initiation of the apoptotic (cell death) cascade by inhibiting the activation of caspases, leading to increased cellular stability and resistance to cytotoxic stress.

Bile Chemistry and Cholesterol Solubilization

The primary chemical action involves competitive displacement, where the hydrophilic UDCA replaces the detergent-like, hydrophobic bile acids in the enterohepatic circulation, thereby shifting the bile acid pool to a less cytotoxic composition. By altering cholesterol metabolism, UDCA reduces the liver's secretion of cholesterol into bile, promoting the formation of soluble mixed micelles. The resulting physiological effect is a dramatic decrease in biliary cholesterol saturation.

Choleretic Action and Facilitated Bile Flow

UDCA functions as a choleretic agent that stimulates the secretion of bicarbonate and water by the bile duct cells (cholangiocytes), partially through modulating membrane transport proteins like the AE2 exchanger. This mechanism increases the volume and alkalinity of the bile, resulting in a ductular flush that facilitates the physical clearance of substances from the biliary tract.

Official Administration Guidelines

Udiliv (ursodeoxycholic acid) is strictly for oral administration, available as capsules, tablets (including scored 500 mg tablets), and in some regions, an oral suspension. The dosing approach is primarily weight-based, with the total daily dose usually administered in divided amounts, and it is mandatory to take the medicine with food to ensure proper absorption.

---

Dosage and Frequency

Indication	Dosing Regimen (Adults)	Administration Schedule
Primary Biliary Cholangitis (PBC)	13-15 mg per kg of body weight per day	Two to four divided doses per day; may shift to a single dose in the evening after initial improvement.
Gallstone Dissolution	8-12 mg per kg of body weight per day	Typically administered in two or three divided doses.
Pediatric (Cystic Fibrosis)	20 mg per kg of body weight per day (children 6-18)	Administered in two or three divided doses.

---

Procedural Use and Duration

Tablets and capsules should be swallowed whole with liquid. If a scored 500 mg tablet is broken for dose adjustment, the segments must be swallowed unchewed. If a dose is missed, it should be taken as soon as it is remembered, unless it is close to the next scheduled dose, in which case the missed dose is skipped; double doses are prohibited.

Treatment duration varies significantly: therapy for PBC is generally long-term and continuous. In contrast, treatment for gallstone dissolution requires a course of 6 to 24 months, continuing for 3 to 4 months after the gallstones are no longer visible on imaging.

Research evidence / Overview of studies for Udiliv (Ursodeoxycholic Acid)

The available research evidence for Udiliv (Ursodeoxycholic Acid) focuses on specific hepatobiliary conditions and was drawn from several types of studies, including controlled clinical trials and large, long-term patient observational studies. Research examined what changes were observed in patients across different time intervals, focusing on disease progression markers and specific outcomes related to each condition.

---

Evidence Studied for Primary Biliary Cholangitis (PBC)

Studies on Biochemical Markers vs. Clinical Outcomes

Research exploring Udiliv's role in Primary Biliary Cholangitis (PBC) has primarily involved two types of study designs. Initial Randomized Controlled Trials (RCTs) were used to explore the outcomes measured over short or intermediate time intervals. These trials closely monitored biochemical markers—specifically, how liver enzyme levels like Alkaline Phosphatase and Bilirubin evolved in the observed populations. These findings describe patterns observed in the studies related to a shift in the measured values of these markers.

Because PBC is a slowly progressing, chronic condition, longer-term evidence is needed. Researchers also monitored large groups of patients using long-term retrospective cohort studies and registry data. These non-randomized studies examined major clinical endpoints, such as how often patients required a liver transplant or patient survival. Evidence suggests an association between the medicine and the monitored long-term clinical endpoints in these large patient groups.

Evidence Studied for Dissolution of Specific Cholesterol Gallstones

Research has explored Udiliv as a subject of study for non-calcified cholesterol gallstones. This was studied for conditions associated with acute or disruptive episodes arising from gallstone presence. Findings describe patterns observed in the studies where dissolution was associated with the specific composition and initial size of the gallstones. Study findings described specific patterns for small, purely cholesterol-based stones. What remains uncertain is the long-term status of patients after treatment concludes; studies report that gallstone recurrence was observed in some studies following the cessation of the medicine.

---

What is Still Uncertain About Udiliv Research

Key limitations include the fact that for many long-term clinical outcomes in PBC, the strongest data are observational rather than randomized, meaning comparative evidence is lacking in that context. Research focusing on patient-reported outcomes describing perceived discomfort, such as fatigue and itching in PBC, has yielded mixed findings and remains an area where certainty remains low. Finally, for CF-related liver disease, the evidence quality varies across studies, and long-term outcomes are not fully established.

Key Studies & References

1. Randomised controlled trials of ursodeoxycholic-acid therapy for primary biliary cirrhosis: a meta-analysis

Common questions about Udiliv (FAQ)

Q: What is Udiliv and what is it used for?

A: Udiliv is a medication containing ursodeoxycholic acid (also known as ursodiol), a type of bile acid that occurs naturally in the body in small amounts.

It is primarily used to dissolve certain types of cholesterol gallstones and to treat liver conditions like Primary Biliary Cirrhosis (PBC), where it improves bile flow and protects liver cells from damage.

Q: How does Udiliv work?

A: Udiliv works in a few ways, depending on the condition being treated:

• For cholesterol gallstones: It reduces the amount of cholesterol produced by the liver and absorbed by the intestines, which makes the bile less saturated with cholesterol. This helps to gradually dissolve cholesterol-based gallstones.
• For liver conditions (like PBC): It replaces the more toxic bile acids in the bile acid pool with itself, reducing the potential harm of these toxic acids to liver cells. It also helps to improve bile flow.

Q: What are the common side effects of Udiliv?

A: The most frequently reported side effects are gastrointestinal, including:

• Diarrhea
• Nausea and/or vomiting
• Abdominal pain
• Pasty or sticky stools

Other potential side effects may include skin rash and itching. If you experience severe or persistent side effects, you should contact your doctor.

Q: Are there any serious side effects to watch out for?

A: Although rare, serious side effects can occur. You should seek immediate medical attention if you experience signs of a severe allergic reaction (like difficulty breathing or swelling of the face, lips, or throat) or signs of worsening liver function, such as:

• Yellowing of the skin or eyes (jaundice)
• Severe, persistent nausea or vomiting
• Dark urine or pale stools

Q: Can Udiliv interact with other medicines?

A: Yes, Udiliv can interact with certain other medications, potentially affecting how they work. It's important to inform your doctor or pharmacist about all other medicines, supplements, or herbal products you are currently taking.

Of particular note are:

• Cholesterol-lowering medicines (like cholestyramine or colestipol) and some antacids, which can reduce the effectiveness of Udiliv. They should be taken at least 2 hours before or after Udiliv.
• Some oral contraceptive pills (those containing high levels of estrogen) may reduce the effect of Udiliv, especially when used to dissolve gallstones.
• Immunosuppressants (like ciclosporin), as Udiliv may increase their effect.

How to Store and Dispose of Udiliv (Ursodeoxycholic Acid)

To ensure product stability, Udiliv (Ursodeoxycholic Acid) must be stored at controlled room temperature, typically 20 C to 25 C (68 F to 77 F). The medicine must be kept from freezing and protected from excessive heat and moisture.

The product should remain in its original container, which must be kept tightly closed. Any unused medicine must be kept out of the sight and reach of children to prevent accidental ingestion.

Disposal must follow local regulatory requirements. Do not dispose of unused or expired Udiliv via wastewater or household trash unless directed by official guidance, such as a drug take-back program.